You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CC-486

Showing 1 - 25 of 953
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 18, 2023

Previously Untreated Peripheral T-cell Lymphoma Trial in Tampa, Saint Louis, New York (CC-486 Administration, CHOP

Active, not recruiting
Has Results
  • Previously Untreated Peripheral T-cell Lymphoma
  • CC-486 Administration
  • CHOP Administration
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

AML Trial in Aurora (Venetoclax, CC-486)

Recruiting
  • AML
  • Aurora, Colorado
  • +1 more
Apr 4, 2022

Hematologic Tumor, Tumors Trial in Gainesville, Baltimore, Houston (CC-486)

Active, not recruiting
  • Hematologic Neoplasm
  • Neoplasms
  • CC-486
  • Gainesville, Florida
  • +2 more
Jan 12, 2023

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (Azacitidine, Pembrolizumab)

Active, not recruiting
  • Melanoma and Other Malignant Neoplasms of Skin
  • Metastatic Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 31, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial in Duarte (Nivolumab, Oral Azacitidine)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Nivolumab
  • Oral Azacitidine
  • Duarte, California
    City of Hope Medical Center
Feb 28, 2022

Hepatic Insufficiency, Tumors Trial in Port Jefferson Station, Cleveland (Onureg, Vidaza)

Not yet recruiting
  • Hepatic Insufficiency
  • Neoplasms
  • Port Jefferson Station, New York
  • +1 more
Jan 13, 2022

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Leukemia, Myeloid, Acute Trial in China (CC-486, Placebo)

Recruiting
  • Leukemia, Myeloid, Acute
  • CC-486
  • Placebo
  • Hefei, Anhui, China
  • +31 more
Jan 10, 2023

Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

Not yet recruiting
  • Untreated Myelodysplastic Syndrome
  • Onureg + Venetoclax
  • Angers, France
  • +9 more
Mar 13, 2023

MDS, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Australia (Azacitidine, CC-486)

Active, not recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Newcastle, New South Wales, Australia
  • +10 more
Mar 29, 2022

T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Oral Azacitidine)

Recruiting
  • T-Cell Large Granular Lymphocyte Leukemia
  • Oral Azacitidine
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 18, 2022

NSCLC Trial in Worldwide (CC-486, Pembrolizumab, Placebo)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • CC-486
  • +2 more
  • Glendale, Arizona
  • +33 more
Jan 12, 2023

Colorectal Cancer Trial in Baltimore (Oral CC-486, Romidepsin, MK-3475)

Completed
  • Colorectal Cancer
  • Oral CC-486
  • +2 more
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Mar 21, 2022

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

MDS, CMML Trial in Florence (CC-486)

Recruiting
  • MDS
  • CMML
  • CC-486
  • Florence, Italy
    AOU Careggi- University of Florence
Mar 16, 2021

MDS Trial in Worldwide (Oral Azacitidine, Durvalumab)

Active, not recruiting
Has Results
  • Myelodysplastic Syndromes
  • New Haven, Connecticut
  • +65 more
Aug 19, 2022

Acute Myelogenous Leukemia (AML) Trial in Summit (CC-486)

Approved for marketing
  • Acute Myelogenous Leukemia (AML)
  • CC-486
  • Summit, New Jersey
    Celgene
Sep 16, 2020

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

NSCLC Trial in Worldwide (nab-paclitaxel IV, CC-486, Duravalumab)

Active, not recruiting
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • nab-paclitaxel IV
  • +2 more
  • San Francisco, California
  • +33 more
Jan 24, 2022

Myeloid Malignancies Trial in Australia, United Kingdom, United States (Magrolimab, Azacitidine, Venetoclax)

Recruiting
  • Myeloid Malignancies
  • Magrolimab
  • +6 more
  • Birmingham, Alabama
  • +12 more
Apr 6, 2022

AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

Not yet recruiting
  • AML, Adult
  • +4 more
  • Amiens, France
  • +19 more
Sep 1, 2023

Acute Myeloid Leukemia, Myelodysplasia Trial in United Kingdom (Oral azacitidine, Matched )

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplasia
  • Oral azacitidine
  • Matched placebo
  • Birmingham, United Kingdom
  • +20 more
Oct 14, 2021